Packed with sensible and sound solutions to common and uncommon diagnostic dilemmas, Rosen’s Diagnosis of Breast Pathology by Needle Core Biopsy, Fifth Edition, helps pathologists in the detection of subtle features which lead to decisive diagnoses. In this award-winning text, Drs. Syed A. Hoda, Raza S. Hoda, and Elaine Zhong provide an entirely updated and sumptuously illustrated guide to correlating pathological, clinical and radiological findings- in the current demanding era of multidisciplinary management.
1. INTRODUCTION - p. 34 2. BACTERIAL INFECTION - p. 34 3. FUNGAL INFECTIONS - p. 36 4. PARASITIC INFESTATION - p. 37 5. VIRAL INFECTION - p. 39 6. 4 Benign Papillary Tumors - p. 41 7. INTRADUCTAL PAPILLOMA - p. 41 8. RADIAL SCLEROSING LESION - p. 52 9. SUBAREOLAR SCLEROSING DUCTAL HYPERPLASIA - p. 58 10. CYSTIC APOCRINE METAPLASIA - p. 58 11. FLORID PAPILLOMATOSIS AND SYRINGOMATOUS ADENOMA OF THE NIPPLE - p. 62 12. COLLAGENOUS SPHERULOSIS - p. 65 13. 5 Adenomyoepithelial and Myoepithelial Neoplasms - p. 71 14. ADENOMYOEPITHELIOMA - p. 73 15. 6 Adenosis and Microglandular Adenosis - p. 82 16. ADENOSIS - p. 82 17. MICROGLANDULAR ADENOSIS - p. 96 18. 7 Fibroepithelial Neoplasms - p. 105 19. SCLEROSING LOBULAR HYPERPLASIA (FIBROADENOMATOID CHANGE) - p. 105 20. FIBROADENOMA - p. 106 21. “FIBROEPITHELIAL TUMOR” AND PHYLLODES TUMOR - p. 115 22. BENIGN PHYLLODES TUMOR - p. 119 23. 8 Ductal Hyperplasia, Atypical Ductal Hyperplasia, and Ductal Carcinoma In Situ - p. 128 24. DUCTAL HYPERPLASIA AND ATYPICAL DUCTAL HYPERPLASIA - p. 128 25. DUCTAL CARCINOMA IN SITU - p. 153 26. DUCTAL CARCINOMA IN SITU AND INVASIVE CARCINOMA - p. 173 27. 9 Invasive Ductal Carcinoma - p. 183 28. NOMENCLATURE - p. 183 29. FROZEN SECTION AND RAPID CYTOLOGIC EVALUATION - p. 185 30. CLINICAL PRESENTATION - p. 185 31. EXTENT/SIZE - p. 186 32. EXTENT/SIZE AND NEEDLE CORE BIOPSY SAMPLES - p. 187 33. MULTIFOCALITY/MULTICENTRICITY - p. 187 34. GRADING - p. 188 35. LYMPHOVASCULAR INVOLVEMENT - p. 192 36. ANGIOGENESIS - p. 194 37. PERINEURAL INVASION - p. 195 38. ABSENCE OF MYOEPITHELIUM - p. 195 39. DUCTAL CARCINOMA IN SITU - p. 197 40. BIOMARKERS - p. 198 41. NEOADJUVANT CHEMOTHERAPY - p. 199 42. TUMOR-INFILTRATING LYMPHOCYTES - p. 200 43. CHANGES AFTER NEOADJUVANT ENDOCRINE AND CHEMOTHERAPY - p. 201 44. MOLECULAR CLASSIFICATION - p. 201 45. MANAGEMENT OF INVASIVE DUCTAL CARCINOMA - p. 204 46. NOTE OF CAUTION - p. 204 47. 10 Tubular Carcinoma - p. 208 48. INTRODUCTION - p. 208 49. CLINICAL PRESENTATION - p. 208 50. 11 Papillary Carcinoma - p. 224 51. INTRODUCTION - p. 224 52. CLINICAL FEATURES - p. 225 53. HISTOPATHOLOGIC EVALUATION - p. 225 54. IMMUNOHISTOCHEMISTRY - p. 228 55. PATTERNS OF PAPILLARY CARCINOMA - p. 230 56. TALL CELL CARCINOMA WITH REVERSED POLARITY - p. 236 57. OTHER PATTERNS - p. 236 58. MOLECULAR STUDIES - p. 238 59. PROGNOSIS AND TREATMENT - p. 238 60. 12 Medullary Carcinoma and Related Carcinomas - p. 241 61. CLINICAL PRESENTATION - p. 242 62. IMAGING STUDIES - p. 242 63. GROSS PATHOLOGY - p. 242 64. HISTOPATHOLOGY - p. 242 65. DIAGNOSING MEDULLARY CARCINOMA ON NEEDLE CORE BIOPSY SAMPLING - p. 245 66. DIFFERENTIATING MEDULLARY CARCINOMA WITH METASTASIS TO INTRAMAMMARY LYMPH NODE - p. 245 67. IMMUNOHISTOCHEMISTRY - p. 245 68. BRCA MUTATIONS AND MEDULLARY CARCINOMA - p. 246 69. PROGNOSIS AND TREATMENT - p. 246 70. MOLECULAR ASPECTS - p. 247 71. RELATIONSHIP BETWEEN MEDULLARY, TRIPLE-NEGATIVE, AND BASAL-LIKE CARCINOMAS - p. 248 72. 13 Metaplastic Carcinomas, Including Low-Grade Adenosquamous Carcinoma - p. 250 73. METAPLASTIC CARCINOMA - p. 250 74. SQUAMOUS CELL CARCINOMA - p. 251 75. METAPLASTIC SPINDLE CELL CARCINOMA - p. 251 76. METAPLASTIC CARCINOMA WITH HETEROLOGOUS ELEMENTS - p. 257 77. METAPLASTIC CARCINOMA WITH CHORIOCARCINOMATOUS MORPHOLOGY - p. 261 78. METASTATIC METAPLASTIC BREAST CARCINOMA - p. 261 79. IMMUNOHISTOCHEMISTRY OF METAPLASTIC CARCINOMA - p. 261 80. TREATMENT AND PROGNOSIS OF METAPLASTIC CARCINOMA - p. 262 81. LOW-GRADE ADENOSQUAMOUS CARCINOMA - p. 263 82. MOLECULAR PATHOLOGY OF METAPLASTIC CARCINOMA - p. 266 83. 14 Mucinous Carcinoma - p. 269 84. CLINICAL PRESENTATION - p. 269 85. HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY - p. 278 86. DIFFERENTIAL DIAGNOSIS OF MUCINOUS LESIONS - p. 278 87. TREATMENT AND PROGNOSIS - p. 282 88. MOLECULAR PATHOLOGY OF MUCINOUS CARCINOMA - p. 283 89. 15 Apocrine Carcinoma - p. 285 90. INTRODUCTION - p. 285 91. CLINICAL FEATURES - p. 285 92. HISTOPATHOLOGIC EVALUATION - p. 285 93. IMMUNOHISTOCHEMISTRY - p. 293 94. DIFFERENTIAL DIAGNOSIS IN NEEDLE CORE BIOPSY MATERIAL - p. 294 95. TREATMENT AND PROGNOSIS - p. 297 96. 16 Adenoid Cystic Carcinoma - p. 299 97. CLINICAL FEATURES - p. 299 98. IMAGING FEATURES - p. 299 99. HISTOPATHOLOGIC EVALUATION - p. 299 100. IMMUNOHISTOCHEMISTRY - p. 303 101. DIFFERENTIAL DIAGNOSIS IN NEEDLE CORE BIOPSY MATERIAL - p. 306 102. MOLECULAR TESTING - p. 308 103. PROGNOSIS AND MANAGEMENT - p. 308 104. 17 Other Special Types of Invasive Breast Carcinoma - p. 310 105. INTRODUCTION - p. 310 106. INVASIVE MICROPAPILLARY CARCINOMA - p. 310 107. INVASIVE CRIBRIFORM CARCINOMA - p. 313 108. SECRETORY CARCINOMA - p. 314 109. CYSTIC HYPERSECRETORY CARCINOMA - p. 318 110. MAMMARY CARCINOMA WITH OSTEOCLAST-LIKE GIANT CELLS - p. 321 111. SMALL CELL CARCINOMA - p. 323 112. GLYCOGEN-RICH CARCINOMA - p. 326 113. LIPID-RICH CARCINOMA - p. 327 114. OTHER RARE TYPES OF CARCINOMA - p. 328 115. 18 Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia - p. 332 116. TERMINOLOGY OF “LOBULAR” LESIONS - p. 332 117. CLINICAL FEATURES - p. 337 118. HISTOPATHOLOGIC EVALUATION - p. 338 119. IMMUNOHISTOCHEMISTRY - p. 343 120. MOLECULAR STUDIES - p. 346 121. DIFFERENTIAL DIAGNOSIS - p. 347 122. MICROINVASIVE LOBULAR CARCINOMA - p. 349 123. PROGNOSIS - p. 350 124. ATYPICAL LOBULAR HYPERPLASIA - p. 352 125. IS EXCISIONAL BIOPSY ALWAYS INDICATED AFTER THE NEEDLE CORE BIOPSY DIAGNOSIS OF LOBULAR CARCINOMA IN SITU? - p. 353 126. IS EXCISIONAL BIOPSY INDICATED AFTER A NEEDLE CORE BIOPSY DIAGNOSIS OF ATYPICAL LOBULAR HYPERPLASIA? - p. 355 127. TREATMENT SUMMARY - p. 355 128. LOBULAR CARCINOMA IN SITU: PRECURSOR LESION OR MARKER OF INVASIVE CARCINOMA? - p. 356 129. 19 Invasive Lobular Carcinoma - p. 359 130. INTRODUCTION - p. 359 131. CLINICAL FEATURES - p. 359 132. HISTOPATHOLOGIC EVALUATION - p. 360 133. IMMUNOHISTOCHEMISTRY - p. 368 134. MOLECULAR STUDIES - p. 370 135. METASTATIC LOBULAR CARCINOMA - p. 371 136. PROGNOSIS - p. 372 137. TREATMENT - p. 372 138. 20 Mesenchymal Lesions - p. 375 139. INTRODUCTION - p. 375 140. (MYO)FIBROBLASTIC - p. 375 141. NEURAL - p. 391 142. SMOOTH MUSCLE - p. 394 143. LIPOMATOUS - p. 396 144. VASCULAR - p. 399 145. OTHER MESENCHYMAL TUMORS - p. 412 146. 21 Lymphoid and Hematopoietic Tumors - p. 421 147. LYMPHOMAS OF THE BREAST - p. 421 148. PLASMA CELL NEOPLASMS - p. 433 149. MYELOID SARCOMA - p. 433 150. HISTIOCYTIC PROLIFERATIONS OF THE BREAST - p. 437 151. INTRAMAMMARY LYMPH NODES - p. 438 152. TISSUE PROCESSING AND ANCILLARY STUDIES - p. 439 153. 22 Metastases From Nonmammary Malignant Neoplasms - p. 443 154. INTRODUCTION - p. 443 155. CLINICAL FEATURES - p. 443 156. IMAGING FEATURES - p. 443 157. HISTOPATHOLOGIC EVALUATION - p. 443 158. COMMON SOURCES OF NMMN INVOLVING THE BREAST - p. 444 159. UNCOMMON SOURCES OF BREAST METASTASES - p. 445 160. OCCULT PRIMARY NEOPLASMS - p. 448 161. METASTATIC PROSTATIC CARCINOMA - p. 448 162. LATE PRESENTATION OF METASTATIC NMMN IN THE BREAST - p. 449 163. AXILLARY LYMPH NODE METASTASES FROM NMMN - p. 449 164. “IMPLANTATION METASTASES” IN THE BREAST - p. 450 165. USE OF IMMUNOSTAINS IN THE DIAGNOSIS OF METASTASES IN THE BREAST - p. 450 166. USE OF IMMUNOSTAINS TO SUPPORT PRIMARY BREAST CARCINOMA - p. 450 167. MANAGEMENT - p. 452 168. MOLECULAR TESTING - p. 453 169. 23 Pathologic Effects of Therapy - p. 455 170. INTRODUCTION - p. 455 171. IRRADIATION - p. 455 172. CHEMOTHERAPY - p. 460 173. ABLATION METHODS - p. 465 174. 24 Men and Children - p. 468 175. BREAST LESIONS IN MALES - p. 468 176. BREAST LESIONS IN CHILDREN AND ADOLESCENTS - p. 475 177. 25 Pathologic Changes and Clinical Complications Associated With Needling Procedures - p. 483 178. INTRODUCTION - p. 483 179. RADIOLOGIC AND HISTOPATHOLOGIC CHANGES IN THE BREAST CAUSED BY NEEDLE CORE BIOPSY - p. 483 180. MAJOR CLINICAL COMPLICATIONS OF NEEDLE CORE BIOPSIES - p. 494 181. NEEDLE CORE BIOPSIES AND RATE OF DISTANT METASTASES - p. 495 182. 26 Processing, Examining, and Reporting of Needle Core Biopsy Specimens - p. 497 183. INTRODUCTION - p. 497 184. BIOPSY TECHNIQUES AND SIZE OF NEEDLES - p. 497 185. TISSUE FIXATION - p. 499 186. REQUISITION FORM - p. 501 187. GROSS EXAMINATION AND DESCRIPTION - p. 502 188. SPECIMEN PROCESSING - p. 503 189. IMAGING MODALITIES - p. 505 190. CALCIFICATIONS - p. 506 191. FROZEN SECTION EXAMINATION - p. 512 192. TOUCH IMPRINT CYTOLOGY - p. 512 193. THE PATHOLOGY REPORT - p. 513 194. STANDARDIZED REPORTING - p. 514 195. ROLE OF THE NEEDLE CORE BIOPSY PATHOLOGY REPORT IN PATIENT CARE - p. 514 196. RECOMMENDATIONS FOR MANAGEMENT IN THE ERA OF DE-ESCALATION - p. 514 197. 27 Biomarker, Molecular, and Other Ancillary Testing - p. 518 198. INTRODUCTION - p. 518 199. TESTING FOR ESTROGEN, PROGESTERONE AND ANDROGEN RECEPTORS - p. 518 200. TESTING FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) - p. 520 201. DETERMINATION OF PROLIFERATION RATE - p. 521 202. KEY MOLECULAR TESTS - p. 523 203. PD-L1 AND OTHER EMERGING TESTS - p. 523 204. Index - p. 527
No hay muestra disponible
No hay ficha técnica disponible
Packed with sensible and sound solutions to common and uncommon diagnostic dilemmas, Rosen’s Diagnosis of Breast Pathology by Needle Core Biopsy, Fifth Edition, helps pathologists in the detection of subtle features which lead to decisive diagnoses. In this award-winning text, Drs. Syed A. Hoda, Raza S. Hoda, and Elaine Zhong provide an entirely updated and sumptuously illustrated guide to correlating pathological, clinical and radiological findings- in the current demanding era of multidisciplinary management.
1. INTRODUCTION - p. 34 2. BACTERIAL INFECTION - p. 34 3. FUNGAL INFECTIONS - p. 36 4. PARASITIC INFESTATION - p. 37 5. VIRAL INFECTION - p. 39 6. 4 Benign Papillary Tumors - p. 41 7. INTRADUCTAL PAPILLOMA - p. 41 8. RADIAL SCLEROSING LESION - p. 52 9. SUBAREOLAR SCLEROSING DUCTAL HYPERPLASIA - p. 58 10. CYSTIC APOCRINE METAPLASIA - p. 58 11. FLORID PAPILLOMATOSIS AND SYRINGOMATOUS ADENOMA OF THE NIPPLE - p. 62 12. COLLAGENOUS SPHERULOSIS - p. 65 13. 5 Adenomyoepithelial and Myoepithelial Neoplasms - p. 71 14. ADENOMYOEPITHELIOMA - p. 73 15. 6 Adenosis and Microglandular Adenosis - p. 82 16. ADENOSIS - p. 82 17. MICROGLANDULAR ADENOSIS - p. 96 18. 7 Fibroepithelial Neoplasms - p. 105 19. SCLEROSING LOBULAR HYPERPLASIA (FIBROADENOMATOID CHANGE) - p. 105 20. FIBROADENOMA - p. 106 21. “FIBROEPITHELIAL TUMOR” AND PHYLLODES TUMOR - p. 115 22. BENIGN PHYLLODES TUMOR - p. 119 23. 8 Ductal Hyperplasia, Atypical Ductal Hyperplasia, and Ductal Carcinoma In Situ - p. 128 24. DUCTAL HYPERPLASIA AND ATYPICAL DUCTAL HYPERPLASIA - p. 128 25. DUCTAL CARCINOMA IN SITU - p. 153 26. DUCTAL CARCINOMA IN SITU AND INVASIVE CARCINOMA - p. 173 27. 9 Invasive Ductal Carcinoma - p. 183 28. NOMENCLATURE - p. 183 29. FROZEN SECTION AND RAPID CYTOLOGIC EVALUATION - p. 185 30. CLINICAL PRESENTATION - p. 185 31. EXTENT/SIZE - p. 186 32. EXTENT/SIZE AND NEEDLE CORE BIOPSY SAMPLES - p. 187 33. MULTIFOCALITY/MULTICENTRICITY - p. 187 34. GRADING - p. 188 35. LYMPHOVASCULAR INVOLVEMENT - p. 192 36. ANGIOGENESIS - p. 194 37. PERINEURAL INVASION - p. 195 38. ABSENCE OF MYOEPITHELIUM - p. 195 39. DUCTAL CARCINOMA IN SITU - p. 197 40. BIOMARKERS - p. 198 41. NEOADJUVANT CHEMOTHERAPY - p. 199 42. TUMOR-INFILTRATING LYMPHOCYTES - p. 200 43. CHANGES AFTER NEOADJUVANT ENDOCRINE AND CHEMOTHERAPY - p. 201 44. MOLECULAR CLASSIFICATION - p. 201 45. MANAGEMENT OF INVASIVE DUCTAL CARCINOMA - p. 204 46. NOTE OF CAUTION - p. 204 47. 10 Tubular Carcinoma - p. 208 48. INTRODUCTION - p. 208 49. CLINICAL PRESENTATION - p. 208 50. 11 Papillary Carcinoma - p. 224 51. INTRODUCTION - p. 224 52. CLINICAL FEATURES - p. 225 53. HISTOPATHOLOGIC EVALUATION - p. 225 54. IMMUNOHISTOCHEMISTRY - p. 228 55. PATTERNS OF PAPILLARY CARCINOMA - p. 230 56. TALL CELL CARCINOMA WITH REVERSED POLARITY - p. 236 57. OTHER PATTERNS - p. 236 58. MOLECULAR STUDIES - p. 238 59. PROGNOSIS AND TREATMENT - p. 238 60. 12 Medullary Carcinoma and Related Carcinomas - p. 241 61. CLINICAL PRESENTATION - p. 242 62. IMAGING STUDIES - p. 242 63. GROSS PATHOLOGY - p. 242 64. HISTOPATHOLOGY - p. 242 65. DIAGNOSING MEDULLARY CARCINOMA ON NEEDLE CORE BIOPSY SAMPLING - p. 245 66. DIFFERENTIATING MEDULLARY CARCINOMA WITH METASTASIS TO INTRAMAMMARY LYMPH NODE - p. 245 67. IMMUNOHISTOCHEMISTRY - p. 245 68. BRCA MUTATIONS AND MEDULLARY CARCINOMA - p. 246 69. PROGNOSIS AND TREATMENT - p. 246 70. MOLECULAR ASPECTS - p. 247 71. RELATIONSHIP BETWEEN MEDULLARY, TRIPLE-NEGATIVE, AND BASAL-LIKE CARCINOMAS - p. 248 72. 13 Metaplastic Carcinomas, Including Low-Grade Adenosquamous Carcinoma - p. 250 73. METAPLASTIC CARCINOMA - p. 250 74. SQUAMOUS CELL CARCINOMA - p. 251 75. METAPLASTIC SPINDLE CELL CARCINOMA - p. 251 76. METAPLASTIC CARCINOMA WITH HETEROLOGOUS ELEMENTS - p. 257 77. METAPLASTIC CARCINOMA WITH CHORIOCARCINOMATOUS MORPHOLOGY - p. 261 78. METASTATIC METAPLASTIC BREAST CARCINOMA - p. 261 79. IMMUNOHISTOCHEMISTRY OF METAPLASTIC CARCINOMA - p. 261 80. TREATMENT AND PROGNOSIS OF METAPLASTIC CARCINOMA - p. 262 81. LOW-GRADE ADENOSQUAMOUS CARCINOMA - p. 263 82. MOLECULAR PATHOLOGY OF METAPLASTIC CARCINOMA - p. 266 83. 14 Mucinous Carcinoma - p. 269 84. CLINICAL PRESENTATION - p. 269 85. HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY - p. 278 86. DIFFERENTIAL DIAGNOSIS OF MUCINOUS LESIONS - p. 278 87. TREATMENT AND PROGNOSIS - p. 282 88. MOLECULAR PATHOLOGY OF MUCINOUS CARCINOMA - p. 283 89. 15 Apocrine Carcinoma - p. 285 90. INTRODUCTION - p. 285 91. CLINICAL FEATURES - p. 285 92. HISTOPATHOLOGIC EVALUATION - p. 285 93. IMMUNOHISTOCHEMISTRY - p. 293 94. DIFFERENTIAL DIAGNOSIS IN NEEDLE CORE BIOPSY MATERIAL - p. 294 95. TREATMENT AND PROGNOSIS - p. 297 96. 16 Adenoid Cystic Carcinoma - p. 299 97. CLINICAL FEATURES - p. 299 98. IMAGING FEATURES - p. 299 99. HISTOPATHOLOGIC EVALUATION - p. 299 100. IMMUNOHISTOCHEMISTRY - p. 303 101. DIFFERENTIAL DIAGNOSIS IN NEEDLE CORE BIOPSY MATERIAL - p. 306 102. MOLECULAR TESTING - p. 308 103. PROGNOSIS AND MANAGEMENT - p. 308 104. 17 Other Special Types of Invasive Breast Carcinoma - p. 310 105. INTRODUCTION - p. 310 106. INVASIVE MICROPAPILLARY CARCINOMA - p. 310 107. INVASIVE CRIBRIFORM CARCINOMA - p. 313 108. SECRETORY CARCINOMA - p. 314 109. CYSTIC HYPERSECRETORY CARCINOMA - p. 318 110. MAMMARY CARCINOMA WITH OSTEOCLAST-LIKE GIANT CELLS - p. 321 111. SMALL CELL CARCINOMA - p. 323 112. GLYCOGEN-RICH CARCINOMA - p. 326 113. LIPID-RICH CARCINOMA - p. 327 114. OTHER RARE TYPES OF CARCINOMA - p. 328 115. 18 Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia - p. 332 116. TERMINOLOGY OF “LOBULAR” LESIONS - p. 332 117. CLINICAL FEATURES - p. 337 118. HISTOPATHOLOGIC EVALUATION - p. 338 119. IMMUNOHISTOCHEMISTRY - p. 343 120. MOLECULAR STUDIES - p. 346 121. DIFFERENTIAL DIAGNOSIS - p. 347 122. MICROINVASIVE LOBULAR CARCINOMA - p. 349 123. PROGNOSIS - p. 350 124. ATYPICAL LOBULAR HYPERPLASIA - p. 352 125. IS EXCISIONAL BIOPSY ALWAYS INDICATED AFTER THE NEEDLE CORE BIOPSY DIAGNOSIS OF LOBULAR CARCINOMA IN SITU? - p. 353 126. IS EXCISIONAL BIOPSY INDICATED AFTER A NEEDLE CORE BIOPSY DIAGNOSIS OF ATYPICAL LOBULAR HYPERPLASIA? - p. 355 127. TREATMENT SUMMARY - p. 355 128. LOBULAR CARCINOMA IN SITU: PRECURSOR LESION OR MARKER OF INVASIVE CARCINOMA? - p. 356 129. 19 Invasive Lobular Carcinoma - p. 359 130. INTRODUCTION - p. 359 131. CLINICAL FEATURES - p. 359 132. HISTOPATHOLOGIC EVALUATION - p. 360 133. IMMUNOHISTOCHEMISTRY - p. 368 134. MOLECULAR STUDIES - p. 370 135. METASTATIC LOBULAR CARCINOMA - p. 371 136. PROGNOSIS - p. 372 137. TREATMENT - p. 372 138. 20 Mesenchymal Lesions - p. 375 139. INTRODUCTION - p. 375 140. (MYO)FIBROBLASTIC - p. 375 141. NEURAL - p. 391 142. SMOOTH MUSCLE - p. 394 143. LIPOMATOUS - p. 396 144. VASCULAR - p. 399 145. OTHER MESENCHYMAL TUMORS - p. 412 146. 21 Lymphoid and Hematopoietic Tumors - p. 421 147. LYMPHOMAS OF THE BREAST - p. 421 148. PLASMA CELL NEOPLASMS - p. 433 149. MYELOID SARCOMA - p. 433 150. HISTIOCYTIC PROLIFERATIONS OF THE BREAST - p. 437 151. INTRAMAMMARY LYMPH NODES - p. 438 152. TISSUE PROCESSING AND ANCILLARY STUDIES - p. 439 153. 22 Metastases From Nonmammary Malignant Neoplasms - p. 443 154. INTRODUCTION - p. 443 155. CLINICAL FEATURES - p. 443 156. IMAGING FEATURES - p. 443 157. HISTOPATHOLOGIC EVALUATION - p. 443 158. COMMON SOURCES OF NMMN INVOLVING THE BREAST - p. 444 159. UNCOMMON SOURCES OF BREAST METASTASES - p. 445 160. OCCULT PRIMARY NEOPLASMS - p. 448 161. METASTATIC PROSTATIC CARCINOMA - p. 448 162. LATE PRESENTATION OF METASTATIC NMMN IN THE BREAST - p. 449 163. AXILLARY LYMPH NODE METASTASES FROM NMMN - p. 449 164. “IMPLANTATION METASTASES” IN THE BREAST - p. 450 165. USE OF IMMUNOSTAINS IN THE DIAGNOSIS OF METASTASES IN THE BREAST - p. 450 166. USE OF IMMUNOSTAINS TO SUPPORT PRIMARY BREAST CARCINOMA - p. 450 167. MANAGEMENT - p. 452 168. MOLECULAR TESTING - p. 453 169. 23 Pathologic Effects of Therapy - p. 455 170. INTRODUCTION - p. 455 171. IRRADIATION - p. 455 172. CHEMOTHERAPY - p. 460 173. ABLATION METHODS - p. 465 174. 24 Men and Children - p. 468 175. BREAST LESIONS IN MALES - p. 468 176. BREAST LESIONS IN CHILDREN AND ADOLESCENTS - p. 475 177. 25 Pathologic Changes and Clinical Complications Associated With Needling Procedures - p. 483 178. INTRODUCTION - p. 483 179. RADIOLOGIC AND HISTOPATHOLOGIC CHANGES IN THE BREAST CAUSED BY NEEDLE CORE BIOPSY - p. 483 180. MAJOR CLINICAL COMPLICATIONS OF NEEDLE CORE BIOPSIES - p. 494 181. NEEDLE CORE BIOPSIES AND RATE OF DISTANT METASTASES - p. 495 182. 26 Processing, Examining, and Reporting of Needle Core Biopsy Specimens - p. 497 183. INTRODUCTION - p. 497 184. BIOPSY TECHNIQUES AND SIZE OF NEEDLES - p. 497 185. TISSUE FIXATION - p. 499 186. REQUISITION FORM - p. 501 187. GROSS EXAMINATION AND DESCRIPTION - p. 502 188. SPECIMEN PROCESSING - p. 503 189. IMAGING MODALITIES - p. 505 190. CALCIFICATIONS - p. 506 191. FROZEN SECTION EXAMINATION - p. 512 192. TOUCH IMPRINT CYTOLOGY - p. 512 193. THE PATHOLOGY REPORT - p. 513 194. STANDARDIZED REPORTING - p. 514 195. ROLE OF THE NEEDLE CORE BIOPSY PATHOLOGY REPORT IN PATIENT CARE - p. 514 196. RECOMMENDATIONS FOR MANAGEMENT IN THE ERA OF DE-ESCALATION - p. 514 197. 27 Biomarker, Molecular, and Other Ancillary Testing - p. 518 198. INTRODUCTION - p. 518 199. TESTING FOR ESTROGEN, PROGESTERONE AND ANDROGEN RECEPTORS - p. 518 200. TESTING FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) - p. 520 201. DETERMINATION OF PROLIFERATION RATE - p. 521 202. KEY MOLECULAR TESTS - p. 523 203. PD-L1 AND OTHER EMERGING TESTS - p. 523 204. Index - p. 527
No hay muestra disponible
No hay ficha técnica disponible
